The CDC recommends a single dose of any FDA-approved RSV vaccine for all adults ages 75 years and older, as well as for 60- ...

As for GBS itself, this neurological ailment can be severe, attacking nerves and warranting hospitalisation for weeks or ...

The FDA has required the manufacturers of the RSV Vaccines Abrysvo and Arexvy to add a new warning to their labels about the ...

The FDA is adding a warning about Guillain-Barré syndrome to the respiratory syncytial virus vaccines manufactured by GSK and ...

On Tuesday, January 7, the FDA announced it would now be requiring GSK and Pfizer’s RSV vaccines to hold warnings of a risk ...

Findings from a postmarketing observational study showed an increased risk of GBS during the 42 days following vaccination.

A post-marketing review by the FDA detected an increased risk of the autoimmune condition in patients inoculated with GSK’s ...

Seasoned biotechnology industry leadership spanning three decades across U.S. and global commercial operations ...

The FDA will require GSK and Pfizer to include on the label of their respiratory syncytial virus (RSV) vaccines a warning ...

Read about vaccine sales, Akums and more in the latest Market Talks covering Health Care.

GSK Plc and Pfizer Inc.’s vaccines for a common respiratory virus must carry warnings that they may be tied to an increased ...

Rare Guillain-Barré Syndrome cases were found after ChAdOx1 vaccine in India; vigilance is urged despite vaccine’s overall safety.